Fig. 1From: Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patientsPeripheral CD4+CD26high are markedly reduced in melanoma patients. Box plots showing the median (25th; 75th percentile) percentage of CD26neg (A), CD26int (B), and CD26high (C) subsets in healthy subjects and melanoma patients. Representative dot plots illustrating CD26 subsets in healthy and melanoma patients are depicted in D and E respectivelyBack to article page